Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab added to Interfant-06 in infants with newly diagnosed MLL-rearranged or high-risk B-precursor ALL
NL-OMON49535Phase 2Completed
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Jul 2018
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Incidence of clinically relevant toxicities. Started Jul 2018; status: completed.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON49535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49535.